22 research outputs found

    ๊ตญ๊ฐ€ ๋Œ€ํ‘œ ์ฝ”ํ˜ธํŠธ ์ž๋ฃŒ๋ฅผ ์ด์šฉํ•œ ์žํ์ŠคํŽ™ํŠธ๋Ÿผ์žฅ์• ์˜ ์ •์‹ ๋ณ‘๋ฆฌ ๊ณต๋ณ‘ ์œ„ํ—˜

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ) -- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ์‚ฌํšŒ๊ณผํ•™๋Œ€ํ•™ ์‹ฌ๋ฆฌํ•™๊ณผ, 2021. 2. ๊ณฝ๊ธˆ์ฃผ.Those with Autism Spectrum Disorder (ASD) have various adversities from childhood to adulthood. For instance, they are exposed to child abuse, bullying by peers, and have a lower quality of life (QoL) compared to the general population. Another major adversity related to ASD is the risk of psychiatric comorbidity. However, research on the psychiatric comorbidity of ASD is scarce and previous studies had various limitations (e.g., only included clinical samples without comparing with general population, studied a single type of psychiatric disorder, included limited age groups, etc.). Therefore, a more comprehensive understanding regarding the risk of psychiatric comorbidity in ASD is needed. The current study conducted an explorative study to investigate the risk of psychiatric comorbidity in ASD using a nationally representative cohort. Also, the risk of psychiatric comorbidity was analyzed by intellectual functioning level and diagnosis timing. Results indicate that those with ASD had significantly higher risk of having comorbid psychiatric disorder compared to the general public. Also, Late-Diagnosed ASD showed higher risk of having certain psychiatric disorders (i.e., depression, OCD, PTSD, ADHD) compared to Early-Diagnosed ASD. Those with High-Functioning ASD had a lower odd of having schizophrenia spectrum and other psychotic disorders and Attention-deficit/hyperactivity disorder and had a higher odd of having depression compared to Low-Functioning ASD. These results imply that those with ASD have a higher risk of psychiatric comorbidity compared to the general population and delayed diagnosis is associated with increased risk for psychiatric comorbidity. Moreover, the risk for psychiatric comorbidity by functioning level varied. Based on the results of this study, screening for psychiatric comorbidity of ASD is needed. Especially, delayed diagnosis seems to be associated with higher risk of psychiatric comorbidity. Therefore, efforts to increase recognition of ASD are needed. Also, intellectual functioning needs to be considered when screening psychiatric comorbidity in ASD.์žํ์ŠคํŽ™ํŠธ๋Ÿผ์žฅ์• ๋ฅผ ๊ฐ€์ง„ ํ™˜์ž๋“ค์€ ์•„๋™๊ธฐ๋ถ€ํ„ฐ ์„ฑ์ธ๊ธฐ๊นŒ์ง€ ๋‹ค์–‘ํ•œ ์–ด๋ ค์›€์„ ๊ฒช๋Š”๋‹ค. ์˜ˆ์ปจ๋Œ€, ์•„๋™ ํญ๋ ฅ, ๋˜๋ž˜ ๊ดด๋กญํž˜, ๋‚ฎ์€ ์‚ถ์˜ ์งˆ, ๋“ฑ์˜ ์–ด๋ ค์›€์„ ๊ฒช๋Š”๋‹ค. ๋”๋ถˆ์–ด, ์žํ์ŠคํŽ™ํŠธ๋Ÿผ์žฅ์• ๋ฅผ ๊ฐ€์ง„ ์ž๋…€์˜ ๋ถ€๋ชจ ๋˜ํ•œ ๊ทน์‹ฌํ•œ ์ŠคํŠธ๋ ˆ์Šค๋ฅผ ํ˜ธ์†Œํ•œ๋‹ค. ์ด๋Ÿฌํ•œ ์žํ์ŠคํŽ™ํŠธ๋Ÿผ์žฅ์•  ํ™˜์ž๋“ค์ด ์ง๋ฉดํ•ด์•ผ ํ•˜๋Š” ๋‹ค๋ฅธ ๋ฌธ์ œ๋Š” ์ •์‹ ์งˆํ™˜ ๊ณต๋ณ‘(psychiatric comorbidity) ์œ„ํ—˜์ด๋‹ค. ์ด๋ฏธ ์žํ์ŠคํŽ™ํŠธ๋Ÿผ์žฅ์• ๋งŒ์œผ๋กœ๋„ ์–ด๋ ค์›€์„ ๊ฒช์ง€๋งŒ, ๋‹ค๋ฅธ ์ •์‹ ์งˆํ™˜ (์˜ˆ์ปจ๋Œ€, ์šฐ์šธ์žฅ์• , ADHD, ๋“ฑ)์„ ๋™๋ฐ˜ํ•˜๊ฒŒ ๋˜๋ฉด, ์‚ถ์˜ ์งˆ์€ ๋” ๋‚ฎ์•„์ง€๋ฉฐ ์ž์‚ด ์œ„ํ—˜ ๋˜ํ•œ ๋†’์•„์ง€๊ฒŒ ๋˜๋Š” ๊ฒƒ์œผ๋กœ ๋ณด๊ณ ๋˜๊ณ  ์žˆ๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ ์ด๋Ÿฐ ์—ฐ๊ตฌ๊ฒฐ๊ณผ๋“ค์—๋„ ๋ถˆ๊ตฌํ•˜๊ณ , ์žํ์ŠคํŽ™ํŠธ๋Ÿผ์žฅ์• ์™€ ์ •์‹ ์งˆํ™˜ ๊ณต๋ณ‘์— ๋Œ€ํ•œ ์—ฐ๊ตฌ๋Š” ๋“œ๋ฌผ๋ฉฐ ๊ตญ๊ฐ€๋‹จ์œ„์˜ ๋ฐ์ดํ„ฐ๋ฅผ ์‚ฌ์šฉํ•œ ์—ฐ๊ตฌ๋Š” ๊ทนํžˆ ๋“œ๋ฌผ๋‹ค. ๋”๋ถˆ์–ด, ๋Œ€๋ถ€๋ถ„์˜ ์—ฐ๊ตฌ๋“ค์€ ํ•œ ์—ฐ๊ตฌ์—์„œ ํ•œ ๊ฐ€์ง€ ์ •์‹ ์งˆํ™˜์„ ์‚ดํŽด๋ณด์•˜์œผ๋ฉฐ, ๋‹ค์–‘ํ•œ ์—ฐ๋ น๋Œ€๊ฐ€ ํฌํ•จ๋œ ๋ฐ์ดํ„ฐ๋ฅผ ์‚ฌ์šฉํ•˜์ง€ ์•Š์•˜๋‹ค๋Š” ์ œํ•œ์ ์ด ์žˆ๋‹ค. ๋ณธ ์—ฐ๊ตฌ๋Š” ๊ตญ๊ฐ€๋ฅผ ๋Œ€ํ‘œํ•  ์ˆ˜ ์žˆ๋Š” ์ž๋ฃŒ๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ, ์žํ์ŠคํŽ™ํŠธ๋Ÿผ์žฅ์• ์˜ ์ •์‹ ์งˆํ™˜ ๊ณต๋ณ‘ ์œ„ํ—˜์„ ์‚ดํŽด๋ณด๋Š” ํƒ์ƒ‰์ ์ธ ์—ฐ๊ตฌ๋ฅผ ์ง„ํ–‰ํ•˜์˜€์œผ๋ฉฐ, ๊ด€๋ จ ์š”์ธ (์ง€์  ์ˆ˜์ค€ ๋ฐ ์ง„๋‹จ ์‹œ๊ธฐ)์— ๋”ฐ๋ผ ๊ทธ ์œ„ํ—˜์— ์ฐจ์ด๊ฐ€ ์žˆ๋Š”์ง€๋ฅผ ์ถ”๊ฐ€์ ์œผ๋กœ ์‚ดํŽด๋ณด์•˜๋‹ค. ์—ฐ๊ตฌ ๊ฒฐ๊ณผ, ์žํ์ŠคํŽ™ํŠธ๋Ÿผ์žฅ์• ๋ฅผ ๊ฐ€์ง„ ํ™˜์ž๋“ค์€ ์ผ๋ฐ˜์ธ์— ๋น„ํ•ด ์กฐํ˜„๋ณ‘, ์–‘๊ทน์„ฑ์žฅ์• , ์šฐ์šธ์žฅ์• , ๋ถˆ์•ˆ์žฅ์• , ๊ฐ•๋ฐ•์žฅ์• , ์™ธ์ƒํ›„์ŠคํŠธ๋ ˆ์Šค์žฅ์• , ์ฃผ์˜๋ ฅ๊ฒฐํ• ๊ณผ์ž‰ํ–‰๋™์žฅ์• ๋ฅผ ๋™๋ฐ˜ํ•  ์œ„ํ—˜์ด ์ผ๋ฐ˜์ธ์— ๋น„ํ•ด ๋†’์€ ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๋‹ค. ๊ณ ๊ธฐ๋Šฅ (high-functioning) ์žํ์ŠคํŽ™ํŠธ๋Ÿผ์žฅ์•  ํ™˜์ž๋“ค์€ ์ €๊ธฐ๋Šฅ (low-functioning) ์žํ์ŠคํŽ™ํŠธ๋Ÿผ ํ™˜์ž๋“ค์— ๋น„ํ•ด ์กฐํ˜„๋ณ‘ ๋ฐ ์ฃผ์˜๋ ฅ๊ฒฐํ• ๊ณผ์ž‰ํ–‰๋™์žฅ์• ๋ฅผ ๊ฐ€์งˆ ์œ„ํ—˜์ด ๋‚ฎ์•˜์œผ๋ฉฐ, ์šฐ์šธ์žฅ์• ๋ฅผ ๊ฐ€์งˆ ์œ„ํ—˜์€ ๋” ๋†’์•˜๋‹ค. ๋”๋ถˆ์–ด, ์ง„๋‹จ์‹œ๊ธฐ์— ๋”ฐ๋ฅธ ์ •์‹ ๋™๋ฐ˜ ์œ„ํ—˜์„ ์‚ดํŽด๋ณด์•˜์„ ๋•Œ, ๋Šฆ์€ ์ง„๋‹จ์„ ๋ฐ›์€ ์žํ์ŠคํŽ™ํŠธ๋Ÿผ์žฅ์•  ํ™˜์ž๋“ค์ด ์ด๋ฅธ ์ง„๋‹จ์„ ๋ฐ›์€ ์žํ์ŠคํŽ™ํŠธ๋Ÿผ์žฅ์•  ํ™˜์ž๋“ค์— ๋น„ํ•ด ์šฐ์šธ์žฅ์• , ๊ฐ•๋ฐ•์žฅ์• , ์™ธ์ƒํ›„์ŠคํŠธ๋ ˆ์Šค์žฅ์• , ์ฃผ์˜๋ ฅ๊ฒฐํ• ๊ณผ์ž‰ํ–‰๋™์žฅ์• ๋ฅผ ๋™๋ฐ˜ํ•  ์œ„ํ—˜์ด ๋†’์€ ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๋‹ค. ์ด๋Ÿฌํ•œ ๊ฒฐ๊ณผ๋Š” ์žํ์ŠคํŽ™ํŠธ๋Ÿผ์žฅ์•  ํ™˜์ž๋“ค์ด ์ผ๋ฐ˜์ธ์— ๋น„ํ•ด ๋‹ค๋ฅธ ์ •์‹ ์งˆํ™˜์„ ๋™๋ฐ˜ํ•  ์œ„ํ—˜์ด ๋†’๋‹ค๋Š” ๊ฒƒ์„ ๋ณด์—ฌ์ฃผ๋ฉฐ, ํŠนํžˆ ์ง„๋‹จ์„ ๋Šฆ๊ฒŒ ๋ฐ›๋Š” ๊ฒƒ์€ ๋‹ค๋ฅธ ์ •์‹ ์งˆํ™˜ ๋™๋ฐ˜์„ ๋†’์ด๋Š” ๊ฒƒ์œผ๋กœ ๋ณด์—ฌ์ง„๋‹ค. ๋˜ํ•œ, ๊ธฐ๋Šฅ ์ˆ˜์ค€(์ง€์  ์ˆ˜์ค€)์— ๋”ฐ๋ฅธ ์ •์‹ ์งˆํ™˜ ๋™๋ฐ˜ ์œ„ํ—˜์€ ์งˆํ™˜์— ๋”ฐ๋ผ ์ƒ์ดํ•œ ๊ฒฐ๊ณผ๊ฐ€ ๋‚˜ํƒ€๋‚œ ๊ฒƒ์œผ๋กœ ๋ณด์•„, ์ง€์  ์ˆ˜์ค€์— ๋”ฐ๋ผ ๋™๋ฐ˜ํ•  ์œ„ํ—˜์ด ๋†’์€ ์ •์‹ ์งˆํ™˜์ด ๋‹ค๋ฅด๋‹ค๋Š” ๊ฒƒ์„ ์‹œ์‚ฌํ•œ๋‹ค. ๊ทธ๋Ÿฌ๋‚˜, ๊ธฐ๋Šฅ ์ˆ˜์ค€์— ๋”ฐ๋ฅธ ์ •์‹ ์งˆํ™˜ ๋™๋ฐ˜ ์œ„ํ—˜์€ ๋ณด๋‹ค ๋งŽ์€ ์—ฐ๊ตฌ๊ฐ€ ํ•„์š”ํ•  ๊ฒƒ์œผ๋กœ ๋ณด์ธ๋‹ค. ๋ณธ ์—ฐ๊ตฌ ๊ฒฐ๊ณผ๋ฅผ ํ† ๋Œ€๋กœ, ์žํ์ŠคํŽ™ํŠธ๋Ÿผ์žฅ์•  ํ™˜์ž๋“ค์„ ๋Œ€์ƒ์œผ๋กœ ์ •์‹ ์งˆํ™˜ ๊ณต๋ณ‘์— ๋Œ€ํ•œ ํ‰๊ฐ€๊ฐ€ ํ•„์š”ํ•˜๋‹ค๋Š” ๊ฒƒ์„ ์•Œ ์ˆ˜ ์žˆ๋‹ค. ํŠนํžˆ, ์ง„๋‹จ ์‹œ๊ธฐ๊ฐ€ ๋Šฆ์„ ๊ฒฝ์šฐ, ์ •์‹ ์งˆํ™˜ ๋™๋ฐ˜ ์œ„ํ—˜์ด ๋†’์•„์ง€๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ์œผ๋ฏ€๋กœ ์ด๋ฅธ ์ง„๋‹จ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ๋„๋ก ์žํ์ŠคํŽ™ํŠธ๋Ÿผ์žฅ์• ์— ๋Œ€ํ•œ ์ธ์‹์ด ๋†’์•„์งˆ ์ˆ˜ ์žˆ๋„๋ก ๋…ธ๋ ฅํ•ด์•ผ ํ•˜๋ฉฐ, ์ง€์  ์ˆ˜์ค€์— ๋”ฐ๋ฅธ ๊ฐœ์ž…์ด ๋‹ค๋ฅด๊ฒŒ ์ง„ํ–‰๋˜์–ด์•ผ ํ•  ๊ฒƒ์œผ๋กœ ๋ณด์ธ๋‹ค.Introduction 1 Psychiatric Comorbidity of ASD 5 Psychiatric Comorbidity of ASD and Functionoing Level 11 Psychiatric Comorbidity of ASD and Diagnosis Timing 14 Methods 18 Data 18 Participant Selection 20 Measures 22 Statistical Analysis 24 Results 26 ASD vs. Non-ASD 26 High-functioniong vs. Low-Functioning ASD 33 Late-Diagnosed vs. Early Diagnosed ASD 39 Discussion 45 ASD and Psychiatric Comorbidity 45 Psychiatric Comorbidity of ASD and Functioning Level 48 Psychiatric Comorbidity of ASD and Diagnosis Timing 51 Implications and Limitations 53 References 56 ๊ตญ๋ฌธ์ดˆ๋ก 78 Appendix 80Maste

    ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ๋ถ€์ž‘์šฉ์œผ๋กœ ์‘๊ธ‰์‹ค์— ๋‚ด์›ํ•œ ์•”ํ™˜์ž์— ๋Œ€ํ•œ ์กฐ์‚ฌ์—ฐ๊ตฌ

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ๊ฐ„ํ˜ธํ•™๊ณผ, 2013. 8. ์ด๋ช…์„ .๊ตญ๋‚ด ์•” ๋ฐœ์ƒ๋ฅ ์€ ๊พธ์ค€ํžˆ ์ฆ๊ฐ€ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ ์ฃผ๋œ ์น˜๋ฃŒ์˜ ํ•˜๋‚˜๋กœ ํ•ญ์•”ํ™”ํ•™์š”๋ฒ•์ด ์‚ฌ์šฉ๋˜๊ณ  ์žˆ์œผ๋‚˜ ์ด๋Š” ๋‹ค์–‘ํ•œ ๋ถ€์ž‘์šฉ๊ณผ ํ•ฉ๋ณ‘์ฆ์„ ์œ ๋ฐœํ•œ๋‹ค. ์ด๋กœ ์ธํ•˜์—ฌ ํ•ญ์•”ํ™”ํ•™์š”๋ฒ•์„ ๋ฐ›๊ณ  ํ‡ด์›ํ•œ ์•”ํ™˜์ž์˜ ์‘๊ธ‰์‹ค ๋ฐฉ๋ฌธ์ด ์ฆ๊ฐ€ํ•˜๊ณ  ์žˆ๋‹ค. ๋ณธ ์—ฐ๊ตฌ๋Š” ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ๋ถ€์ž‘์šฉ์œผ๋กœ ์‘๊ธ‰์‹ค์— ๋‚ด์›ํ•œ ์•”ํ™˜์ž์˜ ํŠน์„ฑ์„ ํŒŒ์•…ํ•˜์—ฌ ํ•ญ์•”ํ™”ํ•™์š”๋ฒ•์„ ๋ฐ›๋Š” ์•”ํ™˜์ž์˜ ๊ต์œก๊ณผ ์ค‘์žฌ๋ฅผ ์œ„ํ•œ ๊ธฐ์ดˆ์ž๋ฃŒ๋ฅผ ์ œ๊ณตํ•˜๊ณ ์ž ์‹œ๋„๋˜์—ˆ๋‹ค. ๋ณธ ์—ฐ๊ตฌ๋Š” ํšก๋‹จ์  ์กฐ์‚ฌ์—ฐ๊ตฌ๋กœ์„œ ์ž๋ฃŒ ์ˆ˜์ง‘์€ 2009๋…„ 1์›”๋ถ€ํ„ฐ 7์›”๊นŒ์ง€ ์„œ์šธ์†Œ์žฌ 3์ฐจ ๋Œ€ํ•™๋ณ‘์› ์‘๊ธ‰์‹ค์— ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ๋ถ€์ž‘์šฉ์œผ๋กœ ๋‚ด์›ํ•œ ์•”ํ™˜์ž 294๋ช…์˜ ์˜๋ฌด๊ธฐ๋ก์„ ํ†ตํ•ด ์กฐ์‚ฌํ•˜์˜€๋‹ค. ์ž๋ฃŒ ์ˆ˜์ง‘ ๋„๊ตฌ๋Š” ๋Œ€์ƒ์ž์˜ ์ธ๊ตฌ์‚ฌํšŒํ•™์  ํŠน์„ฑ, ์งˆ๋ณ‘ ๊ด€๋ จ ํŠน์„ฑ, ์‘๊ธ‰์‹ค ๋‚ด์› ๊ด€๋ จ ํŠน์„ฑ, ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ๋ถ€์ž‘์šฉ์œผ๋กœ ๊ตฌ์„ฑํ•˜์˜€๋‹ค. ์ˆ˜์ง‘๋œ ์ž๋ฃŒ๋Š” SPSS 18.0 ํ†ต๊ณ„ํ”„๋กœ๊ทธ๋žจ์„ ์ด์šฉํ•˜์—ฌ ๊ธฐ์ˆ ํ†ต๊ณ„, t-test, One way ANOVA, Scheffรฉ's test๋กœ ๋ถ„์„ํ•˜์˜€์œผ๋ฉฐ ์—ฐ๊ตฌ์˜ ๊ฒฐ๊ณผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™๋‹ค. 1. ์‘๊ธ‰์‹ค์— ๋‚ด์›ํ•œ ์•”ํ™˜์ž ์ค‘, ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ๋ถ€์ž‘์šฉ์„ ์ฃผํ˜ธ์†Œ๋กœ ๋‚ด์›ํ•œ ํ™˜์ž๋Š” 15.2%๋ฅผ ์ฐจ์ง€ํ–ˆ๋‹ค. 2. ์•”์˜ ์ข…๋ฅ˜ ์ค‘์—์„œ ๊ฐ€์žฅ ๋นˆ๋„์ˆ˜๊ฐ€ ๋†’์€ ์•”์€ ํ์•”(16.7%)์ด์—ˆ๋‹ค. ์ฒซ ์ง„๋‹จ ํ›„ ๊ฒฝ๊ณผ์ผ์€ 2๋…„ ์ด๋‚ด๊ฐ€ 68%, ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ์ด์™ธ์˜ ์น˜๋ฃŒ๋Š” ์ˆ˜์ˆ ์ด 66.7%, ์‚ฌ์šฉ๋œ ํ•ญ์•”์ œ ์ข…๋ฅ˜๋Š” ์•Œํ‚ฌํ™”์ œ์ œ๊ฐ€ 53.1%๋กœ ๊ฐ€์žฅ ๋งŽ์•˜๋‹ค. ํ•ญ์•”ํ™”ํ•™์š”๋ฒ•์„ ๋ฐ›์€ ์ดํ›„ ์‘๊ธ‰์‹ค ๋‚ด์›๊นŒ์ง€ ๊ฒฝ๊ณผ์ผ์€ ํ‰๊ท  9.6์ผ์ด์—ˆ๊ณ , ๋‚ด์› ๋‹น์‹œ ์‘๊ธ‰ ํ™˜์ž ๋ถ„๋ฅ˜์ฒด๊ณ„๋Š” 3๊ตฐ์ด 81.6%๋กœ ๊ฐ€์žฅ ๋งŽ์•˜๋‹ค. ๋Œ€์ƒ์ž์˜ 72.8%๊ฐ€ ์‘๊ธ‰์‹ค ๋‚ด์› ํ›„ ์ž…์›ํ•˜์˜€์œผ๋ฉฐ, ์ž…์› ํ›„ ์ตœ์ข… ์น˜๋ฃŒ ๊ฒฐ๊ณผ๋Š” ๊ท€๊ฐ€๊ฐ€ 93.5%์ด์—ˆ๊ณ  ์‚ฌ๋ง์ด 6.5%์ด์—ˆ๋‹ค. ์‘๊ธ‰์‹ค ๋‚ด์› ํ›„ ์žฌ์›๊ธฐ๊ฐ„์€ ํ‰๊ท  9.2์ผ์ด์—ˆ๋‹ค. 3. ์‘๊ธ‰์‹ค ๋‚ด์› ๋‹น์‹œ ๋Œ€์ƒ์ž์˜ ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ๋ถ€์ž‘์šฉ์˜ ๋นˆ๋„๋Š” ํ˜ˆ์†ŒํŒ ๊ฐ์†Œ(80.6%), ๋นˆํ˜ˆ(74.5%), ํ†ต์ฆ(52.0%), ํ˜ธ์ค‘๊ตฌ ๊ฐ์†Œ(50.7%) ๋“ฑ์˜ ์ˆœ์ด์—ˆ๋‹ค. ์‹์š•๋ถ€์ง„ ์ ์ˆ˜๋Š” ์žฌ์› ๊ธฐ๊ฐ„ 15-21์ผ ๊ตฐ์ด 0-7์ผ ๊ตฐ๋ณด๋‹ค ๋†’์•˜๋‹ค(p=.023). ๋ฐฑํ˜ˆ๊ตฌ ๊ฐ์†Œ ์ •๋„๋Š” ์‘๊ธ‰์‹ค ์น˜๋ฃŒ ํ›„ ์ž…์›ํ•œ ๊ฒฝ์šฐ๊ฐ€ ํ‡ด์›ํ•œ ๊ฒฝ์šฐ๋ณด๋‹ค ๋†’์•˜๊ณ (p=.020), ์ž…์› ํ›„ ์‚ฌ๋งํ•œ ๊ฒฝ์šฐ๊ฐ€ ํ‡ด์›ํ•œ ๊ฒฝ์šฐ๋ณด๋‹ค ๋†’์•˜๋‹ค(p=.027). ๊ธฐ์นจ๊ณผ ํ˜ธํก๊ณค๋ž€ ์ ์ˆ˜๋Š” ์‚ฌ๋งํ•œ ๊ฒฝ์šฐ๊ฐ€ ํ‡ด์›ํ•œ ๊ฒฝ์šฐ๋ณด๋‹ค ๋†’์•˜๋‹ค(p<.05). ๊ฒฐ๋ก ์ ์œผ๋กœ ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ๋ถ€์ž‘์šฉ์œผ๋กœ ์‘๊ธ‰์‹ค์— ๋‚ด์›ํ•œ ์•”ํ™˜์ž๋“ค์—์„œ ์ž…์›์„ ํ•„์š”๋กœ ํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ์•ฝ 3/4๋ฅผ ์ฐจ์ง€ํ•  ์ •๋„๋กœ ๋Œ€๋ถ€๋ถ„์ด์—ˆ๊ณ , ์ž…์› ํ›„ ์‚ฌ๋งํ•œ ๊ฒฝ์šฐ๋„ 6.5%์ธ ๊ฒƒ์„ ๊ฐ์•ˆํ•  ๋•Œ, ํ•ญ์•”ํ™”ํ•™์š”๋ฒ•์„ ๋ฐ›๋Š” ์žฌ๊ฐ€ ์•”ํ™˜์ž๋“ค์„ ์œ„ํ•œ ๋งž์ถคํ˜• ์‘๊ธ‰์ฒด๊ณ„๊ฐ€ ํ•„์š”ํ•จ์„ ๋ณด์—ฌ์ค€๋‹ค. ๋˜ํ•œ ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ๋ถ€์ž‘์šฉ ์ค‘์—์„œ ๋ฐฑํ˜ˆ๊ตฌ ๊ฐ์†Œ, ๊ธฐ์นจ, ํ˜ธํก๊ณค๋ž€ ๋“ฑ์€ ์‚ฌ๋ง๊ณผ ๋ฐ€์ ‘ํ•œ ๊ด€๋ จ์ด ์žˆ๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚˜, ์ด๋“ค์—๊ฒŒ๋Š” ๋”์šฑ ์„ธ์‹ฌํ•˜๊ณ  ์ง‘์ค‘์ ์ธ ๊ด€์‹ฌ๊ณผ ์น˜๋ฃŒ๊ฐ€ ์š”๊ตฌ๋œ๋‹ค. ๊ทธ๋ฆฌ๊ณ  ํ‡ด์› ์‹œ ๊ต์œก์„ ์‹ค์‹œํ•  ๋•Œ์—๋Š” ๋‹ค๋นˆ๋„ ๋ถ€์ž‘์šฉ๊ณผ ๊ด€๋ จ๋œ ํ•ฉ๋ณ‘์ฆ์„ ์˜ˆ๋ฐฉํ•˜๊ณ  ๊ด€๋ฆฌํ•˜๊ธฐ ์œ„ํ•œ ๋‚ด์šฉ์„ ๊ฐ•ํ™”ํ•  ํ•„์š”๊ฐ€ ์žˆ๋‹ค. ๋ณธ ์—ฐ๊ตฌ ๊ฒฐ๊ณผ๋Š” ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ํ›„ ํ‡ด์›ํ•˜๋Š” ์•”ํ™˜์ž์—๊ฒŒ ๋ณด๋‹ค ํšจ๊ณผ์ ์ธ ๊ต์œก ํ”„๋กœ๊ทธ๋žจ์„ ๊ฐœ๋ฐœํ•˜๊ณ  ์žฌ๊ฐ€ ์•”ํ™˜์ž์˜ ์‘๊ธ‰ ์ฆ์ƒ ๊ด€๋ฆฌ ์ฒด๊ณ„๋ฅผ ๋งˆ๋ จํ•˜๋Š” ๋ฐ ๊ธฐ์ดˆ ์ž๋ฃŒ๋กœ ํ™œ์šฉ๋  ์ˆ˜ ์žˆ์„ ๊ฒƒ์ด๋‹ค.๊ตญ๋ฌธ์ดˆ๋ก .................................................................... i I. ์„œ๋ก  ....................................................................... 1 1. ์—ฐ๊ตฌ์˜ ํ•„์š”์„ฑ ..................................................... 1 2. ์—ฐ๊ตฌ ๋ชฉ์  ........................................................... 3 3. ์šฉ์–ด์˜ ์ •์˜ ........................................................ 4 II. ๋ฌธํ—Œ๊ณ ์ฐฐ ............................................................... 5 1. ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ๋ถ€์ž‘์šฉ ........................................... 5 2. ์‘๊ธ‰์‹ค ๋‚ด์› ์•”ํ™˜์ž ๊ด€๋ จ ์—ฐ๊ตฌ ............................... 11 III. ์—ฐ๊ตฌ ๋ฐฉ๋ฒ• ............................................................. 14 1. ์—ฐ๊ตฌ ์„ค๊ณ„ .......................................................... 14 2. ์—ฐ๊ตฌ ๋Œ€์ƒ .......................................................... 14 3. ์—ฐ๊ตฌ ๋„๊ตฌ .......................................................... 15 4. ์ž๋ฃŒ์ˆ˜์ง‘ ์ ˆ์ฐจ .................................................... 17 5. ์œค๋ฆฌ์  ๊ณ ๋ ค ....................................................... 17 6. ์ž๋ฃŒ๋ถ„์„ ๋ฐฉ๋ฒ• .....................................................18 IV. ์—ฐ๊ตฌ ๊ฒฐ๊ณผ ............................................................. 19 1. ์ธ๊ตฌ์‚ฌํšŒํ•™์  ํŠน์„ฑ .............................................. 19 2. ์งˆ๋ณ‘ ๊ด€๋ จ ํŠน์„ฑ ................................................... 21 3. ์‘๊ธ‰์‹ค ๋‚ด์› ๊ด€๋ จ ํŠน์„ฑ ......................................... 25 4. ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ๋ถ€์ž‘์šฉ ........................................... 27 5. ์งˆ๋ณ‘ ๊ด€๋ จ ํŠน์„ฑ์— ๋”ฐ๋ฅธ ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ๋ถ€์ž‘์šฉ ............ 29 6. ์‘๊ธ‰์‹ค ๋‚ด์› ๊ด€๋ จ ํŠน์„ฑ์— ๋”ฐ๋ฅธ ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ๋ถ€์ž‘์šฉ .. 36 V. ๋…ผ์˜ ..................................................................... 44 1. ์‘๊ธ‰์‹ค ๋‚ด์› ์‹œ ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ๋ถ€์ž‘์šฉ ...................... 44 2. ํ•ญ์•”ํ™”ํ•™์š”๋ฒ• ๋ถ€์ž‘์šฉ์œผ๋กœ ์ธํ•œ ์‘๊ธ‰์‹ค ๋‚ด์› ์‹คํƒœ ...... 49 VI. ๊ฒฐ๋ก  ๋ฐ ์ œ์–ธ ......................................................... 52 ์ฐธ๊ณ ๋ฌธํ—Œ ................................................................... 54 ๋ถ€๋ก ......................................................................... 60Maste

    Anti-atherosclerotic effect of 3-hydroxybenzaldehyde

    Get PDF
    Dept. of Medical Science/์„์‚ฌAtherosclerosis is a complex vascular disease caused by thickening arterial wall, infilteration of leukocytes, abnormal proliferation and migration of vascular smooth muscle cells (VSMCs) and the formation of multiple atheromatous plaques within arteries. 3-Hydroxybenzaldehyde (3-HBA) is one of the three isomers of hydroxybenzaldehyde and water-soluble phenolic aldehyde synthesized chemically, but its therapeutic function is unknown. In this study, the inhibitory role of 3-HBA on platelet derivative growth factor-induced migration and proliferation in VSMCs was studied. In addition, 3-HBA diminished signal-transduction involved in the inhibition of platelet derivative growth factor-induced migration and proliferation. Moreover, 3-HBA attenuated platelet aggregation in both in-vivo and ex-vivo conditions and prevented tail vein thrombosis induced by ??-carrageenan injection. In these experiments, 3-HBA reduced blood aggregating velocity and length of thrombus in the tail of rats. These findings suggest a potential therapeutic role of 3-HBA in the treatment of atherosclerosis.ope

    Effects of alkaline reduced water on Echinostoma hortense infection and immune response in C57BL/6 mice

    No full text
    ์ž„์ƒ๋ณ‘๋ฆฌํ•™๊ณผ/์„์‚ฌ[ํ•œ๊ธ€]ํ˜ธ๋ฅดํ…์Šค๊ทน๊ตฌํก์ถฉ์ด ๊ฐ์—ผ ํ›„ ์•Œ์นผ๋ฆฌํ™˜์›์ˆ˜๋ฅผ ๊ธ‰์ดํ•˜์˜€์„ ๋•Œ ๋™๋ฌผ์˜ ๋ฉด์—ญ์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ์„ ์•Œ์•„๋ณด๊ณ ์ž ๋ณธ ์—ฐ๊ตฌ๋ฅผ ์‹œํ–‰ํ•˜์˜€๋‹ค. C57BL/6 ๋งˆ์šฐ์Šค์— ํ˜ธ๋ฅดํ…์Šค๊ทน๊ตฌํก์ถฉ ํ”ผ๋‚ญ์œ ์ถฉ์„ ๋งˆ๋ฆฌ ๋‹น 15๊ฐœ ๊ฒฝ๊ตฌ๊ฐ์—ผ ์‹œํ‚จ ํ›„ 2์ฃผ ๊ฒฝ๊ณผํ•˜์—ฌ ์†Œ์žฅ ๋‚ด ์ถฉ์ฒดํšŒ์ˆ˜์œจ์€ ์•Œ์นผ๋ฆฌํ™˜์›์ˆ˜ ๊ธ‰์ด ํ›„ ์œ ์˜ํ•˜๊ฒŒ ์ฆ๊ฐ€ํ•˜์˜€๋‹ค(p<0.05). ์†Œ์žฅ ์ ๋ง‰์„ ํ™•์ธํ•œ ๊ฒฐ๊ณผ ์•Œ์นผ๋ฆฌํ™˜์›์ˆ˜ ๊ธ‰์ด ํ›„ ๋ฐฐ์„ธํฌ(p<0.001)์™€ IL-4(p<0.01)๊ฐ€ ์œ ์˜ํ•˜๊ฒŒ ์ฆ๊ฐ€ํ•˜์˜€์œผ๋‚˜ TNF-ฮฑ(p<0.01)๋Š” ๊ฐ์†Œํ•˜์˜€๋‹ค. ๋˜ํ•œ RT-PCR์„ ํ†ตํ•ด ๋น„์žฅ ์„ธํฌ์—์„œ ์—ผ์ฆ๋ฐ˜์‘์— ๋Œ€ํ•ด ์—ฐ๊ตฌํ•œ ๊ฒฐ๊ณผ IL-4, IL-5์™€ TNF-ฮฑ, IL-1ฮฒ์€ ์ฆ๊ฐ€ํ•˜์˜€์œผ๋‚˜ IL-10์€ ๊ฐ์†Œํ•˜์˜€๋‹ค. ํ˜ˆ์•ก ๋‚ด ๋ฐฑํ˜ˆ๊ตฌ ์ˆ˜๋Š” ๋น„๊ฐ์—ผ๊ตฐ๋“ค์˜ ๋น„๊ต์—์„œ ๋ฆผํ”„๊ตฌ(p<0.01)์˜ ์ฆ๊ฐ€์™€ ํ˜ธ์ค‘๊ตฌ(p<0.01)์˜ ๊ฐ์†Œ๋ฅผ ๋‚˜ํƒ€๋ƒˆ๋‹ค. ๋ณธ ์—ฐ๊ตฌ์˜ ๊ฒฐ๊ณผ ์•Œ์นผ๋ฆฌํ™˜์›์ˆ˜์˜ ์–ด๋– ํ•œ ์„ฑ์ƒ์ด ์žฅ์ ๋ง‰์— ์ง์ ‘์ ์œผ๋กœ ์ž‘์šฉํ•˜์—ฌ ๋ฐฐ์„ธํฌ์™€ cytokine ๋“ฑ์— ์˜ํ–ฅ์„ ๋ฏธ์ณค์œผ๋ฉฐ ์ด๋Š” ํ˜ธ๋ฅดํ…์Šค๊ทน๊ตฌํก์ถฉ๊ณผ ์ˆ™์ฃผ์™€์˜ ์ƒํ˜ธ์ž‘์šฉ์— ๊ด€์—ฌํ•˜์—ฌ ์ถฉ์ฒด ๋ฐฐ์ถœ์— ์˜ํ–ฅ์„ ์ฃผ๋Š” ๊ฒƒ์œผ๋กœ ์ถ”์ธก๋œ๋‹ค. [์˜๋ฌธ]The effects of alkaline reduced water (ARW) on the immunity of mouse infected with Echinostoma hortense were investigated. C57BL/6 mice were fed on conventional water (normal control group) or ARW (ARW group) without infection, or infected with 15 E. hortense with conventional water (infected control group) or ARW (ARW+E. hortense group) feeding. As parameters of worm expulsion rate, number of goblet cell in intestine, cytokine mRNA expression, and number of peripheral blood leukocytes were examined 2 weeks after the infection. The worm expulsion rate was significantly increased in the ARW group compared with the ARW+E. hortense group (p<0.05). The number of the goblet cells was significantly increased in the infected control group compared with the ARW+E. hortense group (p<0.001). The level of IL-4 was significantly increased in the normal control group compared with the ARW group (p<0.01). However, the level of TNF-ฮฑ was significantly decreased in the ARW+E. hortense group compared with the infected control group (p<0.01). In the spleen, the levels of IL-4, IL-5, TNF-ฮฑ, and IL-1ฮฒ mRNA were increased in the ARW+E. hortense group compared with the infected control group. However, the level of IL-10 mRNA in the ARW group was decreased compared with normal control group. Compared with the normal control group, the number of lymphocytes was increased in the ARW group (p<0.01) and the number of neutrophils was decreased in the ARW group (p<0.01).In conclusion, ARW is effective on the number of goblet cells and the expression levels of some cytokines in intestine in E. hortense-infected C57BL/6 mouse. It was supposed that ARW may modulate the infectivity of E. hortense in the mouse.ope

    ํ† ์ง€์ž„๋Œ€๋ถ€ ์ฃผํƒ ์œ ํ˜•์„ ์ค‘์‹ฌ์œผ๋กœ

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :ํ–‰์ •๋Œ€ํ•™์› ๊ณต๊ธฐ์—…์ •์ฑ…ํ•™๊ณผ,2019. 8. ๋ฐ•์ƒ์ธ.๊ทธ๋™์•ˆ ์ฃผํƒ์€ ์†Œ์œ ์˜ ๊ฐœ๋…์œผ๋กœ ์ธ์‹๋˜์–ด ์™”๋Š”๋ฐ ๊ทธ ์ด์œ ๋Š” ์†Œ์œ ๋œ ์ฃผํƒ์€ ์ง€์†์ ์ธ ๊ฒฝ์ œ๋ฐœ์ „์— ๋”๋ถˆ์–ด ๊ทธ ๊ฐ€๊ฒฉ์ด ์ƒ์Šนํ•˜์˜€์œผ๋ฉฐ ์„œ๋ฏผ๋“ค์—๊ฒŒ ๊ฐ€์žฅ ์ค‘์š”ํ•œ ์ž์‚ฐ์œผ๋กœ ์ธ์‹๋˜์–ด ์™”๊ธฐ ๋•Œ๋ฌธ์ด๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ 2008๋…„ ๊ธˆ์œต์œ„๊ธฐ ์ดํ›„ ์ฃผํƒ์€ ์ „์„ธ๊ฐ€๊ฒฉ์˜ ๊ธ‰๋“ฑ๊ณผ ๊ธ‰๊ฒฉํ•œ ์›”์„ธํ™”๋กœ ์ธํ•ด ์ฃผ๊ฑฐ๋น„ ๋ถ€๋‹ด์ด ํ™•๋Œ€๋˜์–ด ์†Œ์œ ์—์„œ ๊ฑฐ์ฃผ์˜ ๊ฐœ๋…์œผ๋กœ ํƒˆ๋ฐ”๊ฟˆ๋˜๊ณ  ์žˆ๋‹ค. ๋˜ํ•œ ๊ณต๊ณต์˜ ์žฌ์›์œผ๋กœ ์ง€์›๋˜์–ด ์˜จ ์ž„๋Œ€์ฃผํƒ์˜ ๊ฒฝ์šฐ ๋ง‰๋Œ€ํ•œ ๊ฑด์„ค๋น„์— ๋น„ํ•ด ์ˆ˜์ž…์€ ์ €์กฐํ•˜์—ฌ ๊ณต๊ณต์˜์—ญ์˜ ๋ถ€์‹คํ™”๋กœ ์ด์–ด์ ธ, ๊ณต๊ณต๊ณผ ๋ฏผ๊ฐ„์ด ๊ฐ™์ด ํ˜‘์—…ํ•œ ์ฃผํƒ์˜ ํ˜•ํƒœ์ธ ์‚ฌํšŒ์ฃผํƒ์˜ ํ•„์š”์„ฑ์ด ๋Œ€๋‘๋˜์—ˆ๋‹ค. ์šฐ๋ฆฌ๋‚˜๋ผ์˜ ๊ฒฝ์šฐ 2012๋…„ ๊ฒฝ ๋ถ€ํ„ฐ ๋น„์˜๋ฆฌ ์กฐํ•ฉ ๋ฐ ํ˜‘๋™์กฐํ•ฉ ๋“ฑ ์‚ฌํšŒ์  ๊ฒฝ์ œ์ฃผ์ฒด์™€ ํ•™๊ณ„๋ฅผ ์ค‘์‹ฌ์œผ๋กœ ๋ฏผ๊ฐ„์ฐจ์›์—์„œ ์ฒญ๋…„ ์ฃผ๊ฑฐ ๋ฌธ์ œ์™€ ๋„์‹œ์žฌ์ƒ ๋ฌธ์ œ, ๊ทธ๋ฆฌ๊ณ  ๊ณต๊ณต์ž„๋Œ€ ์ฃผํƒ์˜ ํ•œ๊ณ„์— ๋Œ€ํ•œ ๊ณ ๋ฏผ์ด ์‹œ์ž‘๋˜๊ณ , ์‹คํ—˜์  ๋ชจ๋ธ์ด ์‹œ๋„ ๋˜์—ˆ๋‹ค. ์„œ์šธ์‹œ์˜ ๊ฒฝ์šฐ๋Š” 2015๋…„ ใ€Œ์„œ์šธ์‹œ ์‚ฌํšŒ์ฃผํƒ ํ™œ์„ฑํ™” ์ง€์› ๋“ฑ์— ๊ด€ํ•œ ์กฐ๋ก€ใ€๋ฅผ ์ œ์ •ํ•˜๋ฉด์„œ ๋ณธ๊ฒฉ์ ์œผ๋กœ ์‚ฌํšŒ์  ๊ฒฝ์ œ์กฐ์ง์˜ ๋น„์˜๋ฆฌ ์ž„๋Œ€์ฃผํƒ ๊ณต๊ธ‰์„ ์ง€์›ํ•˜๊ฒŒ ๋˜์—ˆ๋‹ค. ๊ตญ๊ฐ€์ ์œผ๋กœ๋Š” ๊ทธ๋™์•ˆ 2004๋…„ 2์›” ์ €์†Œ๋“์„œ๋ฏผ์ธต ์ฃผ๊ฑฐ๋ณต์ง€ ํ™•๋Œ€๋ฐฉ์•ˆ์„ ๋ฐœํ‘œํ•œ ํ›„ ๋งค์ž…์ž„๋Œ€์ฃผํƒ์„ 2004๋…„๊ฒฝ๋ถ€ํ„ฐ ๊ณต๊ธ‰ํ•œ ํ›„ ๊ณต๊ณต์ด ๊ด€๋ฆฌํ•˜๋‹ค๊ฐ€ ์ด ํ›„ ๋น„์˜๋ฆฌ ๋‹จ์ฒด๊ฐ€ ๊ด€๋ฆฌํ•˜๋ฉด์„œ ์‚ฌํšŒ์  ์ฃผํƒ์˜ ๊ฐœ๋…์ด ๋„์ž…๋˜์—ˆ๋‹ค. ์ด ํ›„ ์ •๋ถ€๋Š” 17.10.17 ์‚ฌํšŒ์ ๊ฒฝ์ œ ํ™œ์„ฑํ™” ๋ฐฉ์•ˆ์„ ๋ฐœํ‘œํ•˜๊ณ , 17.11.29 ์ฃผ๊ฑฐ๋ณต์ง€ ๋กœ๋“œ๋งต์—์„œ ใ€Œ์‚ฌํšŒ์  ๊ฒฝ์ œ์ฃผ์ฒด์— ์˜ํ•œ ์ž„๋Œ€์ฃผํƒ(์‚ฌํšŒ์ฃผํƒ)๊ณต๊ธ‰ ํ™œ์„ฑํ™”ใ€๋ฅผ ๋ฐœํ‘œํ•˜์˜€๋Š”๋ฐ, ์‚ฌํšŒ์  ๊ธฐ์—…, ์‚ฌํšŒ์  ํ˜‘๋™์กฐํ•ฉ ๋“ฑ ์‚ฌํšŒ์  ๊ฒฝ์ œ์ฃผ์ฒด๋ฅผ ์ž„๋Œ€์ฃผํƒ๊ณต๊ธ‰ยท์šด์˜์ฃผ์ฒด๋กœ ์œก์„ฑํ•˜์—ฌ ๊ณต๊ณต๋ถ€๋ฌธ ์ง€์›์˜ ์‚ฌ๊ฐ์ง€๋Œ€๋ฅผ ํ•ด์†Œํ•˜๊ณ ์ž ํ•˜์˜€๋‹ค. ์•„์ง๊นŒ์ง€ ๋ช…ํ™•ํžˆ ์‚ฌํšŒ์ฃผํƒ์— ๋Œ€ํ•œ ๋ช…ํ™•ํ•œ ๋ฒ•์  ์ •์˜๋Š” ์—†์œผ๋‚˜, ์„ ํ–‰ ์—ฐ๊ตฌ ๋ฐ ํ•ด์™ธ์‚ฌ๋ก€๋ฅผ ํ†ตํ•ด ์‚ดํŽด๋ณธ ๊ฒฐ๊ณผ ์‚ฌํšŒ์ฃผํƒ์€ โ‘  ์„œ๋ฏผ ๋ฐ ์ฃผ๊ฑฐ์•ฝ์ž์˜ ์ฃผ๊ฑฐ๋ณต์ง€ ํ–ฅ์ƒ์„ ๋ชฉ์ ์œผ๋กœ, โ‘ก ๊ณต๊ณต์˜ ์ง€์›์„ ๋ฐ›์€ ์‚ฌํšŒ์  ๊ฒฝ์ œยท๋น„์˜๋ฆฌ์ฃผ์ฒด๊ฐ€ โ‘ข ์ž…์ฃผ์ž์™€ ์ง€์—ญ์˜ ์ฐธ์—ฌ์™€ ๊ฐ•ํ•œ ์—ฐ๋Œ€๋ฅผ ๋ฐ”ํƒ•์œผ๋กœ โ‘ฃ ๊ณต๊ธ‰ยท์šด์˜ํ•˜๋Š” ์–‘์งˆ์˜ ์ฃผํƒ์ด๋ผ๊ณ  ํ•  ์ˆ˜ ์žˆ๋‹ค. ๊ฒฐ๊ตญ ์‚ฌํšŒ์ฃผํƒ์€ ๊ณต๊ณต๊ณผ ๋ฏผ๊ฐ„์˜ ํ˜‘๋ ฅ์„ ํ†ตํ•ด ์ œ๊ณต๋˜๋Š” ๋น„์˜๋ฆฌ ๋ชฉ์ ์˜ ์ฃผํƒ์œผ๋กœ ๋ฏผ๊ฐ„์ฃผ์ฒด์— ์˜ํ•ด์„œ ๊ณต๊ธ‰ยท์šด์˜๋˜์ง€๋งŒ, ํ† ์ง€, ๊ธˆ์œต ๋“ฑ์˜ ๋ถ€๋ฌธ์—์„œ ๊ณต์  ์ง€์›์ด ์ด๋ฃจ์–ด์ง€๊ธฐ ๋•Œ๋ฌธ์— ์ž„๋Œ€๋ฃŒ์™€ ์ž…์ฃผ์ž์˜ ์ž๊ฒฉ ์ œํ•œ ๋“ฑ ๊ณต๊ณต์„ฑ์ด ๊ฐ•ํ•œ ์ฃผํƒ์„ ์˜๋ฏธํ•œ๋‹ค๊ณ  ๋ณผ ์ˆ˜ ์žˆ๋‹ค. ๋˜ํ•œ ์ž„๋Œ€๋ฃŒ๋ถ„์„ ์—ฐ๊ตฌ๋ฅผ ์‚ดํŽด๋ณด๋ฉด ๊ทธ๋™์•ˆ ์‰์–ดํ•˜์šฐ์Šค์˜ ์ž„๋Œ€๋ฃŒ ๋ถ„์„ ๋ฐ ์ผ๋ฐ˜ ์ฃผํƒ๊ฐ€๊ฒฉ์— ๋Œ€ํ•œ ์ž„๋Œ€๋ฃŒ ๋ถ„์„ ๋“ฑ์€ ์กด์žฌํ•ด ์™”์œผ๋‚˜, 2015๋…„๋ถ€ํ„ฐ ๊ณต๊ธ‰๋œ ์‚ฌํšŒ์ฃผํƒ์˜ ๊ฒฝ์šฐ๋Š” ์ž„๋Œ€๋ฃŒ์— ๋Œ€ํ•œ ๋ถ„์„์ด ์—†์–ด ์ตœ๊ทผ ๋Œ€๋‘๋˜๊ณ  ์žˆ๋Š” ์‚ฌํšŒ์ฃผํƒ์— ๋Œ€ํ•ด ์ž„๋Œ€๋ฃŒ ๋ถ„์„์ด ํ•„์š”ํ•˜๋‹ค๊ณ  ์ƒ๊ฐ๋˜์–ด ์‚ฌํšŒ์ฃผํƒ ๊ณต๊ธ‰์œ ํ˜•์„ ํ† ์ง€์ž„๋Œ€๋ถ€, ๋นˆ์ง‘, ๋ฆฌ๋ชจ๋ธ๋งํ˜•์œผ๋กœ ๋‚˜๋ˆ„๊ณ  ์œ ํ˜•์— ๋”ฐ๋ฅธ ์ž„๋Œ€๋ฃŒ ๋ถ„์„์„ ์‹ค์‹œํ•˜์˜€๋‹ค. ๊ธฐ์ˆ  ํ†ต๊ณ„ ๊ฒฐ๊ณผ๋Š” ํ† ์ง€์ž„๋Œ€๋ถ€์˜ ๊ฒฝ์šฐ๋Š” ๋Œ€์ง€๋ฉด์ ๊ณผ ๊ฑด์ถ•๋ฉด์ ์ด ์ƒ๋Œ€์ ์œผ๋กœ ํฌ๋ฉฐ, ๊ฒฝ์‚ฌ๋„๋Š” ์ƒ๋Œ€์ ์œผ๋กœ ์™„๊ฒฝ์‚ฌ์— ์œ„์น˜ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ๋Œ€์ง€๋ชจ์–‘๋„ ํƒ€ ์œ ํ˜•๋ณด๋‹ค ์ •๋ฐฉํ˜•์— ๊ฐ€๊นŒ์šด ๋ชจ์–‘์„ ๋„๊ณ , ๋Œ€์ง€์˜ ๋ฐฉํ–ฅ์€ ๋‚จํ–ฅ์„ ํฌํ•จํ•˜๊ณ  ์žˆ๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋‹ค๋ฅธ ์œ ํ˜•๋ณด๋‹ค ๋†’์•„, ๊ฑด๋ฌผ์ด ์ง€๋‹Œ ํ™˜๊ฒฝ์ด ํƒ€ ์œ ํ˜•๋ณด๋‹ค ์šฐ์ˆ˜ํ•˜๋‹ค๊ณ  ๋ณผ ์ˆ˜ ์žˆ๋‹ค. ๋˜ํ•œ ์‚ฌํšŒ์ฃผํƒ ๊ณต๊ธ‰ ์œ ํ˜•์— ๋”ฐ๋ฅธ ํšŒ๊ท€๋ถ„์„ ๊ฒฐ๊ณผ๋Š” ํ†ต์ œ๋ณ€์ˆ˜ ํ†ต์ œ ์ „์—๋Š” 1์ธ๋‹น ์ž„๋Œ€๋ฃŒ์˜ ๊ฒฝ์šฐ ๋ฆฌ๋ชจ๋ธ๋ง, ๋นˆ์ง‘, ํ† ์ง€์ž„๋Œ€๋ถ€ ์ˆœ์œผ๋กœ ์ž„๋Œ€๋ฃŒ๊ฐ€ ๋‚ฎ์•˜์œผ๋‚˜, ํ†ต์ œ๋ณ€์ˆ˜ ๋“ฑ์„ ํ†ต์ œํ•˜๊ณ  ํšŒ๊ท€๋ถ„์„ ํ›„์—๋Š” 1์ธ๋‹น ์ž„๋Œ€๋ฃŒ์˜ ๊ฒฝ์šฐ๋Š” ํ† ์ง€์ž„๋Œ€๋ถ€ ๋ฐฉ์‹์ด ๋ฆฌ๋ชจ๋ธ๋ง ๋ฐฉ์‹์— ๋น„ํ•ด 95%์‹ ๋ขฐ์ˆ˜์ค€์—์„œ ์ž„๋Œ€๋ฃŒ๊ฐ€ 44,298์› ์ €๋ ดํ•จ์„ ๋ณด์—ฌ์ฃผ๊ณ  ์žˆ๋‹ค. ๋‹ค์Œ์œผ๋กœ ๋ฆฌ๋ชจ๋ธ๋ง, ๋นˆ์ง‘์˜ ์œ ํ˜•์œผ๋กœ ์ž„๋Œ€๋ฃŒ๊ฐ€ ์ƒ์Šนํ•˜๋Š” ๋ชจ์Šต์„ ๋ณด์ผ ์ˆ˜ ์žˆ์—ˆ๋‹ค. ํ† ์ง€์ž„๋Œ€๋ถ€ ๋ฐฉ์‹์˜ ๊ฒฝ์šฐ, 1์ธ๋‹น ๋ฉด์ ์ด ๊ฐ€์žฅ ๋„“๊ณ , ๋ฐฉ๊ณผ ์š•์‹ค์˜ ๊ณต๋™์‚ฌ์šฉ ์—ฌ๋ถ€๊ฐ€ ์ž‘์•„, ํ˜ธ์‹ค ํŠน์„ฑ์œผ๋กœ ๋ณด๋ฉด ๊ฑฐ์ฃผ ํ™˜๊ฒฝ ์ธก๋ฉด์—์„œ ์šฐ์ˆ˜ํ•˜๊ณ , ๋น„์šฉ๋„ ์ €๋ ดํ•จ์„ ์•Œ ์ˆ˜ ์žˆ๋‹ค. 1์ธ๋‹น ์ž„๋Œ€๋ฃŒ/๋‹จ์œ„๋ฉด์ ์„ ๋ถ„์„ํ•œ ๊ฒฐ๊ณผ๋Š” ํ† ์ง€์ž„๋Œ€๋ถ€ ํ˜•์‹์ด ๋ฆฌ๋ชจ๋ธ๋ง ๋Œ€๋น„ 95%์‹ ๋ขฐ์ˆ˜์ค€์—์„œ ๋ถ€(-)์˜ ๊ด€๊ณ„๋ฅผ ๋ณด์ด๊ณ  ์žˆ๊ณ , ๋นˆ์ง‘์˜ ๊ฒฝ์šฐ๋Š” ๋ฆฌ๋ชจ๋ธ๋ง ๋Œ€๋น„ 99%์‹ ๋ขฐ์ˆ˜์ค€์—์„œ ์ •์˜ ๊ด€๊ณ„๋ฅผ ๋ณด์ด๊ณ  ์žˆ์–ด ๋นˆ์ง‘์˜ ๊ฒฝ์šฐ๊ฐ€ ์ž„๋Œ€๋ฃŒ๊ฐ€ ๋†’์Œ์„ ์•Œ ์ˆ˜ ์žˆ๋‹ค. ๋˜ํ•œ 1์ธ๋‹น ์ž„๋Œ€๋ฃŒ/1์ธ๋‹น ๋ฉด์ ์€ ์‹ค์ œ๋กœ 1์ธ๋‹น ๋ถ€๋‹ดํ•˜๋Š” ์ฃผ๊ฑฐ๋น„ ๋ถ€๋‹ด๋ฅ ๋กœ ๋ณด๊ณ  ๋ถ„์„์„ ํ•˜์˜€๋Š”๋ฐ, ๊ทธ ๊ฒฐ๊ณผ๋Š” ํ† ์ง€์ž„๋Œ€๋ถ€์˜ ๊ฒฝ์šฐ ๋ฆฌ๋ชจ๋ธ๋ง ๋Œ€๋น„ 95% ์‹ ๋ขฐ์ˆ˜์ค€์—์„œ ์œ ์˜๋ฏธํ•˜๊ฒŒ ๋ถ€์˜ ๊ด€๊ณ„๋ฅผ ๋ณด์ด๋ฉฐ, ๋นˆ์ง‘์˜ ๊ฒฝ์šฐ๋Š” ๋ฆฌ๋ชจ๋ธ๋ง ๋Œ€๋น„ 99%์‹ ๋ขฐ์ˆ˜์ค€์—์„œ ์œ ์˜๋ฏธํ•œ ์ •์˜ ๊ด€๊ณ„๋ฅผ ๋ณด์—ฌ ์ฃผ์—ˆ๋‹ค. ๊ทธ๋ฆฌ๊ณ  ์ข…์†๋ณ€์ˆ˜์— ๋กœ๊ทธ๊ฐ’์„ ์ทจํ•œ ๋ฐ˜๋กœ๊ทธํ•จ์ˆ˜์˜ ๊ฒฝ์šฐ๋Š” ์ถ”์ •๊ณ„์ˆ˜์˜ ๊ฐ’์ด ํ•ด๋‹น ํŠน์„ฑ์˜ ๋ณ€ํ™”์— ๋”ฐ๋ฅธ ๋ถ€๋™์‚ฐ ๊ฐ€๊ฒฉ์˜ ๋ณ€ํ™”์œจ์˜ ๊ทผ์‚ฌ์น˜๋ฅผ ๋ณด์—ฌ์ฃผ๊ธฐ ๋•Œ๋ฌธ์— ๊ฒฐ๊ณผ ํ•ด์„์ด ๋‹จ์ˆœํ•˜์—ฌ ๋ถ„์„ํ•˜๊ธฐ๋„ ํ•˜์˜€๋‹ค. ํ† ์ง€ ๊ณต๊ธ‰์ž ์ธก๋ฉด์—์„œ ๋ณธ ์ž„๋Œ€๋ฃŒ๋Š” LH ํ† ์ง€์˜ ๊ฒฝ์šฐ๊ฐ€ ๊ธˆ์œต์ง€์› ๋“ฑ์ด ํ™œ๋ฐœํžˆ ์ด๋ฃจ์–ด์ง€๊ณ  ์žˆ์–ด ์ž„๋Œ€๋ฃŒ๊ฐ€ ์ €๋ ดํ•  ๊ฒƒ์ด๋ผ๋Š” ๊ฐ€์„ค๋กœ ์—ฐ๊ตฌ๋ฅผ ์ง„ํ–‰ํ•˜์˜€๋Š”๋ฐ, ํ†ต์ œ ์ „ ๊ธฐ์ˆ ํ†ต๊ณ„๋ฅผ ์‚ดํŽด๋ณด๋ฉด 1์ธ๋‹น ์ž„๋Œ€๋ฃŒ์˜ ๊ฒฝ์šฐ LH ๊ณต๊ธ‰ ํ† ์ง€์˜ ํ† ์ง€์ž„๋Œ€๋ถ€ ๋ฐฉ์‹์ด ๋น„์‹ธ๊ฒŒ ์ฑ…์ •๋˜์—ˆ์œผ๋‚˜, ์ž…์ง€ํŠน์„ฑ๊ณผ ๊ฑด๋ฌผํŠน์„ฑ, ํ˜ธ์‹คํŠน์„ฑ์„ ํ†ต์ œ ํ•œ ํ›„ ๋ถ„์„ํ•œ ๊ฒฐ๊ณผ SH ๊ณต๊ธ‰ํ† ์ง€์˜ 1์ธ๋‹น ์ž„๋Œ€๋ฃŒ๊ฐ€ 99%์‹ ๋ขฐ์ˆ˜์ค€์—์„œ ์ •์˜ ์œ ์˜๋ฏธํ•œ ์˜ํ–ฅ์„ ๋ฏธ์น˜๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๋‹ค. ์ด๋Š” ํ† ์ง€์ž„๋Œ€๋ถ€ ์ฃผํƒ์˜ ๊ฒฝ์šฐ๋„ ํ† ์ง€๊ณต๊ธ‰์ฃผ์ฒด์— ๋”ฐ๋ผ ๊ธˆ์œต์ง€์›์ด ์ƒ์ดํ•˜๊ณ , LH ๊ณต๊ธ‰ํ† ์ง€์˜ ๊ฒฝ์šฐ ๋Œ€์ง€ ๋ฉด์ ์ด ํฌ๊ณ , ๋ฐฉ์„ ๊ณต๋™์œผ๋กœ ์‚ฌ์šฉํ•˜๋Š” ์ˆ˜์น˜๊ฐ€ ์กฐ๊ธˆ ๋” ๋†’์œผ๋ฉฐ, ์„œ์šธ์‹œ ๊ณต๊ธ‰ ํ† ์ง€์˜ ๊ฒฝ์šฐ๋ณด๋‹ค ๊ณต์‹œ์ง€๊ฐ€๊ฐ€ ๋‚ฎ์€ ๊ฒฝ๊ธฐ๋„๊ถŒ์— ์œ„์น˜ํ•œ ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์•„ ๋ถ„์„๋œ ๊ฒฐ๊ณผ๋ผ ๋ณผ ์ˆ˜ ์žˆ๋‹ค. ๊ฒฐ๊ณผ์ ์œผ๋กœ 1์ธ๋‹น ์ž„๋Œ€๋ฃŒ๋กœ ์‚ดํŽด๋ณธ ์‚ฌํšŒ์ฃผํƒ์˜ ๊ฒฝ์šฐ๋Š” LH ๊ณต๊ธ‰ํ† ์ง€์˜ ํ† ์ง€์ž„๋Œ€๋ถ€ ๋ฐฉ์‹์ด 1์ธ๋‹น ์ž„๋Œ€๋ฃŒ ์ง€์ถœ์ด ์ ๊ณ , ๊ฑฐ์ฃผํ™˜๊ฒฝ๋„ ์–‘ํ˜ธํ•˜๊ธฐ ๋•Œ๋ฌธ์— ๊ฒ€ํ† ๋˜์–ด์•ผ ํ•  ์‚ฌํšŒ์ฃผํƒ ๊ณต๊ธ‰ ์œ ํ˜•์œผ๋กœ ํŒ๋‹จ๋œ๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ ์‚ฌํšŒ์ฃผํƒ ๊ณต๊ธ‰์œ ํ˜•์— ๋”ฐ๋ผ ๊ณต์ ์ธ ์ง€์› ๊ธˆ์•ก, ๊ธˆ์œต์ง€์› ์กฐ๊ฑด๋“ฑ๋„ ๋ฐ์ดํ„ฐ๋ฒ ์ด์Šคํ™” ํ•˜์—ฌ, ํ†ต์ œํ•˜์—ฌ์•ผ๋งŒ ๋”์šฑ ๋ช…ํ™•ํ•œ ๊ฒฐ๊ณผ๊ฐ€ ๋‚˜์˜ค๋ฆฌ๋ผ ํŒ๋‹จ๋˜์–ด ์ถ”๊ฐ€ ๋ฐ์ดํ„ฐ์˜ ํ™•์ถฉ, ์‚ฌํšŒ์ž„๋Œ€์ฃผํƒ ์ œ๋„์˜ ์ •๋ฆฝ ๋“ฑ์˜ ๋…ผ์˜๊ฐ€ ํ•„์š”ํ•˜์—ฌ ์ถ”๊ฐ€์ ์ธ ์—ฐ๊ตฌ๊ฐ€ ์š”๊ตฌ๋œ๋‹ค.์ œ 1 ์žฅ ์„œ ๋ก  1 ์ œ 1 ์ ˆ ์—ฐ๊ตฌ์˜ ๋ชฉ์  ๋ฐ ํ•„์š”์„ฑ 1 ์ œ 2 ์ ˆ ์—ฐ๊ตฌ์˜ ๋‚ด์šฉ ๋ฐ ๋ฒ”์œ„ 3 ์ œ 2 ์žฅ ์ด๋ก ์  ๋ฐฐ๊ฒฝ ๋ฐ ์„ ํ–‰์—ฐ๊ตฌ 6 ์ œ 1 ์ ˆ ์ž„๋Œ€์ฃผํƒ ์ •์ฑ…์˜ ๋ณ€ํ™” 6 1. ๊ณต๊ณต์ž„๋Œ€์ฃผํƒ์ •์ฑ… 6 2. ์‚ฌํšŒ์ฃผํƒ ๋ฐ ์‚ฌํšŒ์ ๊ธฐ์—…ยทํ˜‘๋™์กฐํ•ฉ 10 1) ์‚ฌํšŒ์ฃผํƒ์˜ ๊ฐœ๋… 10 (1) ์œ ๋Ÿฝ์ฃผ์š”๊ตญ๊ฐ€์—์„œ์˜ ์‚ฌํšŒ์ฃผํƒ ๊ฐœ๋… 10 (2) ๊ตญ๋‚ด์—์„œ์˜ ์‚ฌํšŒ์ฃผํƒ ๊ฐœ๋… 14 2) ์‚ฌํšŒ์ ๊ธฐ์—…๊ณผ ์˜ˆ๋น„ ์‚ฌํšŒ์  ๊ธฐ์—… 15 3) ํ˜‘๋™์กฐํ•ฉ๊ณผ ์‚ฌํšŒ์  ํ˜‘๋™์กฐํ•ฉ 17 4) ๊ตญ๋‚ด์˜ ์‚ฌํšŒ์ฃผํƒ์˜ ํ˜„ํ™ฉ 19 (1) ์ค‘์•™์ •๋ถ€์˜ ์‚ฌํšŒ์ฃผํƒ ์ •์ฑ… ํ˜„ํ™ฉ 19 (2) ์ง€๋ฐฉ์ •๋ถ€์˜ ์‚ฌํšŒ์ฃผํƒ ์ •์ฑ… ํ˜„ํ™ฉ 22 ์ œ 2 ์ ˆ ์„ ํ–‰์—ฐ๊ตฌ์˜ ๊ฒ€ํ†  ๋ฐ ๋ณธ ์—ฐ๊ตฌ์˜ ์ฐจ๋ณ„์„ฑ 23 1. ์„ ํ–‰์—ฐ๊ตฌ ๊ฒ€ํ†  23 2. ๋ณธ ์—ฐ๊ตฌ์˜ ์ฐจ๋ณ„์„ฑ 25 ์ œ 3 ์žฅ ์—ฐ๊ตฌ๋ฌธ์ œ ๋ฐ ์—ฐ๊ตฌ๋ฐฉ๋ฒ• 26 ์ œ 1 ์ ˆ ์—ฐ๊ตฌ๋ฌธ์ œ 26 1. ์—ฐ๊ตฌ๋ชจํ˜• ๋ฐ ๋ณ€์ˆ˜ ์„ ์ • 26 1) ๋…๋ฆฝ๋ณ€์ˆ˜ 27 2) ์ข…์†๋ณ€์ˆ˜ 27 3) ํ†ต์ œ๋ณ€์ˆ˜ 28 2. ๊ฐ€์„ค์˜ ์„ค์ • 29 ์ œ 2 ์ ˆ ์—ฐ๊ตฌ๋ฐฉ๋ฒ• 30 1. ์ž๋ฃŒ์ˆ˜์ง‘ 30 2. ์—ฐ๊ตฌ๋ฐฉ๋ฒ• 33 ์ œ 4 ์žฅ ์—ฐ๊ตฌ๊ฒฐ๊ณผ 35 ์ œ 1 ์ ˆ ๊ธฐ์ˆ ํ†ต๊ณ„ ๋ถ„์„ 35 1. ์ข…์†๋ณ€์ˆ˜์˜ ๋ถ„์„ 36 2. ํ†ต์ œ๋ณ€์ˆ˜์˜ ๋ถ„์„ 39 ์ œ 2 ์ ˆ ์ƒ๊ด€๊ด€๊ณ„ ๋ถ„์„ 43 ์ œ 3 ์ ˆ ์—ฐ๊ตฌ ๊ฐ€์„ค์˜ ๊ฒ€์ • 46 1. ์‚ฌํšŒ์ฃผํƒ ๊ณต๊ธ‰์œ ํ˜•์— ๋”ฐ๋ฅธ ๋ถ„์„ 46 2. ํ† ์ง€์ž„๋Œ€๋ถ€ ์œ ํ˜•์—์„œ ํ† ์ง€๊ณต๊ธ‰์ž์— ๋”ฐ๋ฅธ ๋ถ„์„ 53 ์ œ 5 ์žฅ ๊ฒฐ๋ก  60 ์ œ 1 ์ ˆ ์—ฐ๊ตฌ์˜ ์š”์•ฝ 60 ์ œ 2 ์ ˆ ์—ฐ๊ตฌ์˜ ํ•œ๊ณ„ 61 ์ฐธ๊ณ ๋ฌธํ—Œ 63 Abstract 66Maste
    corecore